ey0017.2-2 | Neonatal Hypoglycaemia | ESPEYB17
SC Chen
, A Dastamani
, D Pintus
, D Yau
, S Aftab
, L Bath
, C Swinburne
, L Hunter
, A Giardini
, G Christov
, S Senniappan
, I Banerjee
, MG Shaikh
, P Shah
To read the full abstract: Clin Endocrinol (Oxf). 2019 Dec;91(6):770775. PMID: 31520536Diazoxide is the first line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). The vast majority of patients tolerate diazoxide well without any major complications. However, diazoxide is known to cause several side effects including hypertrichosis, neutropaenia, thrombocytop...